DE19164145T1 - Schnellauflösungsformulierung einer calcium-rezeptor-aktivverbindung - Google Patents
Schnellauflösungsformulierung einer calcium-rezeptor-aktivverbindung Download PDFInfo
- Publication number
- DE19164145T1 DE19164145T1 DE19164145.5T DE19164145T DE19164145T1 DE 19164145 T1 DE19164145 T1 DE 19164145T1 DE 19164145 T DE19164145 T DE 19164145T DE 19164145 T1 DE19164145 T1 DE 19164145T1
- Authority
- DE
- Germany
- Prior art keywords
- tablet according
- weight
- tablet
- composition
- cinacalcet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Tablette, umfassend(a) von 10 Gew.-% bis 40 Gew.-% Cinacalcet HCl;(b) von 45 bis 85 Gew.-% mindestens eines Verdünnungsmittels, das aus Stärke, mikrokristalliner Cellulose, Dicalciumphosphat, Lactose, Sorbitol, Mannitol, Saccharose, Methyldextrinen und Mischungen davon ausgewählt wird; und(c) von 1 bis 5 Gew.-% mindestens eines Bindemittels; wobei der Gewichtsprozentsatz sich auf das Gesamtgewicht der Zusammensetzung bezieht; und wobei die Tablette ein Auflösungsprofil in 0,05 N HCl aufweist, das durch einen Auflösungstest bestimmt wird wird, der in einer USP 2-Apparatur bei einer Temperatur von 37°C und einer Rotationsgeschwindigkeit von 75 U/min durchgeführt wird, bei dem die Freisetzung von 50% bis 125% einer Zielmenge des Cinacalcets aus der Zusammensetzung nicht später als 30 Minuten nach Beginn des Tests erzielt wird.
Claims (13)
- Tablette, umfassend (a) von 10 Gew.-% bis 40 Gew.-% Cinacalcet HCl; (b) von 45 bis 85 Gew.-% mindestens eines Verdünnungsmittels, das aus Stärke, mikrokristalliner Cellulose, Dicalciumphosphat, Lactose, Sorbitol, Mannitol, Saccharose, Methyldextrinen und Mischungen davon ausgewählt wird; und (c) von 1 bis 5 Gew.-% mindestens eines Bindemittels; wobei der Gewichtsprozentsatz sich auf das Gesamtgewicht der Zusammensetzung bezieht; und wobei die Tablette ein Auflösungsprofil in 0,05 N HCl aufweist, das durch einen Auflösungstest bestimmt wird wird, der in einer USP 2-Apparatur bei einer Temperatur von 37°C und einer Rotationsgeschwindigkeit von 75 U/min durchgeführt wird, bei dem die Freisetzung von 50% bis 125% einer Zielmenge des Cinacalcets aus der Zusammensetzung nicht später als 30 Minuten nach Beginn des Tests erzielt wird.
- Tablette gemäß
Anspruch 1 , in der die Freisetzung von 70% bis 110% einer Zielmenge des Cinacalcets aus der Zusammensetzung nicht später als 30 Minuten nach Beginn des Tests erzielt wird. - Tablette gemäß
Anspruch 1 , in der das Bindemittel aus Povidon, Hydroxypropylmethylcellulose, Dihydroxypropylcellulose und Natriumcarboxylmethylcellulose ausgewählt wird. - Tablette gemäß
Anspruch 1 , die ferner von 0,05% bis 5% mindestens eines Additivs umfasst, das aus Gleitmitteln, Schmiermitteln und Haftmitteln ausgewählt wird, wobei sich der Gewichtsprozentsatz auf das Gesamtgewicht der Zusammensetzung bezieht. - Tablette gemäß
Anspruch 4 , in der das Gleitmittel aus einem oder mehreren von Magnesiumstearat, Calciumstearat, Stearinsäure, Glycerylbehenat, hydriertem Pflanzenöl, Glycerinfumarat ausgewählt wird. - Tablette gemäß
Anspruch 5 , in der das Gleitmittel Magnesiumstearat ist. - Tablette gemäß
Anspruch 6 , die ferner 0,05% bis 1,5% Magnesiumstearat enthält. - Tablette gemäß
Anspruch 1 , bei der das zur Herstellung der Tablette verwendete Cinacalcet HCl ein kristallines Pulver ist. - Tablette gemäß
Anspruch 1 , bei der die Teilchengröße D50 der Cinacalcet-HCl-Teilchen kleiner als oder gleich etwa 50µm ist. - Tablette gemäß
Anspruch 1 , wobei das Granulat D50 mittels Siebanalyse gemessen wird. - Tablette gemäß
Anspruch 1 , ferner umfassend 0,05 bis 1,5 Gew.-% kolloidales Siliciumdioxid, bezogen auf das Gesamtgewicht der Zusammensetzung. - Tablette gemäß
Anspruch 1 , in der das mindestens eine Sprengmittel aus Crospovidon, Natriumstärkeglycolat, Croscarmellose-Natrium und Mischungen der vorgenannten Stoffe ausgewählt wird. - Tablette gemäß
Anspruch 1 , die ferner ein Überzugsmaterial umfasst, das Hydroxypropylmethylcellulose umfasst.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50221903P | 2003-09-12 | 2003-09-12 | |
US502219P | 2003-09-12 | ||
EP19164145.5A EP3578175B1 (de) | 2003-09-12 | 2004-09-10 | Schnellauflösungsformulierung einer calcium-rezeptor-aktivverbindung |
Publications (1)
Publication Number | Publication Date |
---|---|
DE19164145T1 true DE19164145T1 (de) | 2021-04-29 |
Family
ID=34434844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE19164145.5T Pending DE19164145T1 (de) | 2003-09-12 | 2004-09-10 | Schnellauflösungsformulierung einer calcium-rezeptor-aktivverbindung |
Country Status (30)
Country | Link |
---|---|
US (7) | US7829595B2 (de) |
EP (8) | EP2821067B1 (de) |
JP (3) | JP5026077B2 (de) |
KR (1) | KR101332058B1 (de) |
CN (1) | CN1946382B (de) |
AR (1) | AR045637A1 (de) |
AU (1) | AU2004279318C1 (de) |
BR (2) | BR122018013029B1 (de) |
CA (1) | CA2536487C (de) |
CY (5) | CY1119609T1 (de) |
DE (1) | DE19164145T1 (de) |
DK (6) | DK1663182T4 (de) |
EA (1) | EA013425B1 (de) |
ES (7) | ES2401769T5 (de) |
HR (1) | HRP20130114T4 (de) |
HU (5) | HUE044822T2 (de) |
IL (1) | IL173737A (de) |
IS (1) | IS3027B (de) |
MX (1) | MXPA06002616A (de) |
MY (1) | MY142046A (de) |
NO (1) | NO335739B1 (de) |
NZ (1) | NZ545498A (de) |
PL (6) | PL3395339T3 (de) |
PT (6) | PT3260117T (de) |
SG (1) | SG146608A1 (de) |
SI (6) | SI3395340T1 (de) |
TR (4) | TR201910180T4 (de) |
TW (1) | TWI344363B (de) |
WO (1) | WO2005034928A1 (de) |
ZA (1) | ZA200602710B (de) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100074949A1 (en) * | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
ES2401769T5 (es) | 2003-09-12 | 2020-07-01 | Amgen Inc | Formulación de disolución rápida de cinacalcet HCl |
RS53895B1 (en) | 2004-06-24 | 2015-08-31 | Vertex Pharmaceuticals Incorporated | ATP-BINDING CASSETTE TRANSPORT MODULATORS |
ATE443038T1 (de) * | 2005-05-16 | 2009-10-15 | Teva Pharma | Verfahren zur herstellung von cinacalcet hydrochlorid |
US7294735B2 (en) * | 2005-05-23 | 2007-11-13 | Teva Pharmaceutical Industries Ltd. | Purification of cinacalcet |
CA2605764A1 (en) * | 2005-05-23 | 2006-11-30 | Teva Pharmaceutical Industries Ltd. | Amorphous cinacalcet hydrochloride and preparation thereof |
US8729085B2 (en) | 2005-05-26 | 2014-05-20 | Dainippon Sumitomo Pharma Co., Ltd. | Pharmaceutical composition |
ES2400693T3 (es) * | 2005-09-02 | 2013-04-11 | Amgen Inc. | Regulación del equilibrio de fluido intestinal usando calcimiméticos |
WO2007062147A1 (en) * | 2005-11-22 | 2007-05-31 | Teva Pharmaceutical Industries Ltd. | Crystal forms of cinacalcet hci and processes for their preparation |
PL3219705T3 (pl) | 2005-12-28 | 2020-08-10 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne amorficznych postaci n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4-dihydro-4-oksochinolino-3-karboksyamidu |
SI3095447T1 (sl) | 2006-02-03 | 2022-02-28 | Opko Renal, Llc | Zdravljenje pomanjkanja vitamina D s 25-hidroksivitaminom D2 in 25-hidroksivitaminom D3 |
WO2007112280A1 (en) * | 2006-03-23 | 2007-10-04 | Amgen Inc. | Methods and compositions for making and using polymorphs of cinacalcet |
JP2009535350A (ja) * | 2006-04-27 | 2009-10-01 | テバ ファーマシューティカル インダストリーズ リミティド | シナカルセット塩基の調製法 |
WO2007127445A2 (en) * | 2006-04-27 | 2007-11-08 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of cinacalcet base |
PT2679228T (pt) | 2006-06-21 | 2018-04-16 | Opko Ireland Global Holdings Ltd | Terapia utilizando um agente de repleção de vitamina d e um agente de substituição hormonal de vitamina d |
WO2008000422A1 (en) * | 2006-06-27 | 2008-01-03 | Sandoz Ag | Amorphous form of cinacalcet |
WO2008027522A2 (en) * | 2006-09-01 | 2008-03-06 | Teva Pharmaceutical Industries Ltd. | Solid composites of a calicum receptor-active compound |
WO2008063645A1 (en) * | 2006-11-20 | 2008-05-29 | Teva Pharmaceutical Industries Ltd. | Process for preparing cinacalcet |
WO2008064202A2 (en) * | 2006-11-20 | 2008-05-29 | Dr. Reddy's Labortories, Ltd. | Modified-release formulations of calcium receptor-active compounds |
TWI454479B (zh) | 2007-03-06 | 2014-10-01 | Amgen Inc | 變異之活動素受體多肽及其用途 |
CA2701638A1 (en) * | 2007-04-02 | 2008-10-09 | Concert Pharmaceuticals Inc. | Pharmaceutical calcimimetics |
PT2148661E (pt) | 2007-04-25 | 2013-03-06 | Proventiv Therapeutics Llc | Composições orais de libertação controlada compreendendo um composto de vitamina d e veículo ceroso |
PL2148684T3 (pl) | 2007-04-25 | 2013-06-28 | Cytochroma Inc | Sposób leczenia niedoboru i deficytu witaminy D |
CA2691196C (en) * | 2007-06-21 | 2016-05-24 | Amgen Inc. | Methods of synthesizing cinacalcet and salts thereof |
US20090093652A1 (en) * | 2007-08-16 | 2009-04-09 | Michal Rafilovich | Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof |
WO2010071689A2 (en) * | 2008-05-05 | 2010-06-24 | Medichem, S.A. | Process for controlling the particle size of a 3-(trifluoromethyl)phenyl]-1-aminopropane derivative |
US20100256184A1 (en) * | 2008-08-13 | 2010-10-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
EP2334284B1 (de) | 2008-09-25 | 2012-08-08 | Ratiopharm GmbH | Kompaktiertes cinacalcet |
WO2010086129A1 (en) | 2009-01-27 | 2010-08-05 | Rathiopharm Gmbh | Inclusion complex comprising cinacalcet and cyclodextrin |
SI2821400T1 (en) | 2009-03-20 | 2018-02-28 | Vertex Pharmaceuticals Incorporated | A process for the manufacture of a transmembrane conductivity regulator in cystic fibrosis |
US8765676B2 (en) | 2009-05-27 | 2014-07-01 | Leo Pharma A/S | Calcium sensing receptor modulating compounds and pharmaceutical use thereof |
US8785494B2 (en) | 2009-05-27 | 2014-07-22 | Leo-Pharma A/S | Calcium sensing receptor modulating compounds and pharmaceutical use thereof |
EP2314286A1 (de) | 2009-10-21 | 2011-04-27 | Ratiopharm GmbH | Schmelzgranuliertes Cinacalcet |
PT2552484T (pt) | 2010-03-29 | 2020-04-03 | Opko Ireland Global Holdings Ltd | Métodos e composições para redução dos níveis de parafróides |
CN109745313A (zh) | 2010-08-11 | 2019-05-14 | 德雷克塞尔大学 | 治疗帕金森病中运动障碍的d3多巴胺受体激动剂 |
LT2642980T (lt) * | 2010-11-23 | 2020-05-25 | Amgen Inc. | Pediatrinė vaisto forma |
CN103228619A (zh) | 2010-11-26 | 2013-07-31 | 利奥制药有限公司 | 钙传感受体活性化合物 |
EP2643290A1 (de) | 2010-11-26 | 2013-10-02 | Leo Pharma A/S | Casr-aktive verbindungen |
RU2013128973A (ru) | 2010-11-26 | 2015-01-10 | Лео Фарма А/С | Соединения, активные в отношении кальций-чувствительных рецепторов |
RU2013128950A (ru) | 2010-11-26 | 2015-01-10 | Лео Фарма А/С | Замещенные циклопентилазины в качестве casr-активных соединений |
SG11201403367YA (en) | 2011-12-19 | 2014-07-30 | Amgen Inc | Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof |
EP2804588B1 (de) | 2012-01-17 | 2017-09-06 | Zentiva Saglik Urunleri San. Ve Tic. A.S. | Verfahren zur herstellung von cinacalcetzusammensetzungen zur direkttablettierung |
EP2819670A1 (de) | 2012-02-27 | 2015-01-07 | Vertex Pharmaceuticals Incorporated | Pharmazeutische zusammensetzung und verabreichung davon |
CN102885792A (zh) * | 2012-10-12 | 2013-01-23 | 华润赛科药业有限责任公司 | 盐酸西那卡塞的口服固体速释制剂 |
PL2730279T3 (pl) | 2012-11-09 | 2015-12-31 | K H S Pharma Holding Gmbh | Preparaty cynakalcetu o natychmiastowym uwalnianiu |
HUE051406T2 (hu) | 2012-11-14 | 2021-03-01 | Grace W R & Co | Biológiailag aktív anyagot és rendezetlen szervetlen oxidot tartalmazó kompozíciók |
RU2662562C2 (ru) * | 2012-12-21 | 2018-07-26 | Синтон Б.В. | Композиция в форме таблеток, содержащая гидрохлорид цинакалцета |
EP2951205B1 (de) | 2013-02-01 | 2021-08-11 | Santa Maria Biotherapeutics, Inc. | Anti-aktivin-a-verbindungen zur behandlung vom ovarialkrebs |
KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 d 방출 제형 |
CA2915432C (en) * | 2013-06-26 | 2019-03-05 | Jubilant Life Sciences Limited | Disintegrant free composition of cinacalcet |
EP3116487A1 (de) | 2014-03-14 | 2017-01-18 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Pharmazeutische zusammensetzung von cinacalcet |
WO2015150944A1 (en) | 2014-03-29 | 2015-10-08 | Wockhardt Limited | Solid oral pharmaceutical compositions comprising cinacalcet or a salt thereof |
EP3193925A2 (de) * | 2014-08-07 | 2017-07-26 | OPKO Ireland Global Holdings, Ltd. | Adjunktive therapie mit 25-hydroxyvitamin d |
JP6746569B2 (ja) | 2014-10-07 | 2020-08-26 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | 嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーターの共結晶 |
CN104721164B (zh) * | 2015-03-25 | 2017-07-07 | 河北仁合益康药业有限公司 | 一种盐酸西那卡塞薄膜衣片组合物 |
MX2018011820A (es) | 2016-03-28 | 2019-01-24 | Opko Ireland Global Holdings Ltd | Metodos de tratamiento con vitamina d. |
JPWO2017170858A1 (ja) | 2016-03-31 | 2019-02-14 | インターセプト ファーマシューティカルズ, インコーポレイテッド | 溶出性に優れた経口製剤 |
US11331283B2 (en) * | 2017-08-16 | 2022-05-17 | Unichem Laboratories Ltd | Pharmaceutical compositions comprising cinacalcet hydrochloride and one or more binders |
WO2019186516A1 (en) | 2018-03-30 | 2019-10-03 | Ftf Pharma Private Limited | Liquid dosage forms of cinacalcet or salt thereof |
US10920483B2 (en) | 2018-10-25 | 2021-02-16 | Mark Mutchnik | Window seal for preventing water penetration |
RU2750761C2 (ru) * | 2019-09-17 | 2021-07-02 | Общество с ограниченной ответственностью "АМЕДАРТ" | Ядро таблетки, содержащей цинакальцета гидрохлорид |
BR112022017133A2 (pt) * | 2020-02-29 | 2022-10-11 | Kempharm Inc | Composições compreendendo pró-drogas de metilfenidato, processos de fabricação e uso das mesmas |
CN112546010A (zh) * | 2020-12-02 | 2021-03-26 | 普莱赛思(天津)生命科技有限公司 | 一种肾病药物组合物及其制备方法 |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4517179A (en) | 1983-04-29 | 1985-05-14 | Pennwalt Corporation | Rapid dissolving, uniform drug compositions and their preparation |
EP0315249A1 (de) | 1987-11-02 | 1989-05-10 | Merck & Co. Inc. | Phthalazinessigsäure-Zusammensetzung und Tablette |
EP0357815A1 (de) | 1988-09-06 | 1990-03-14 | Siemens Aktiengesellschaft | Schaltbare Konstantstromquelle mit I2L-Gattern |
EP0373417A1 (de) | 1988-11-30 | 1990-06-20 | Schering Corporation | Diltiacem-Formulierung mit protrahierter Wirkstoffabgabe |
NZ231897A (en) | 1988-12-30 | 1992-09-25 | Monsanto Co | Dry water-soluble granular composition comprising glyphosate and a liquid surfactant |
US5126145A (en) | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
US4931286A (en) | 1989-04-19 | 1990-06-05 | Aqualon Company | High gloss cellulose tablet coating |
DD299322A5 (de) * | 1989-09-21 | 1992-04-09 | Maschinenfabrik Rieter Ag,Ch | Verfahren und vorrichtung zur feinreinigung von textilfasern |
US5011068A (en) * | 1989-12-05 | 1991-04-30 | Progressive Tool & Industries Co. | Automotive body framing system |
RU2147574C1 (ru) | 1991-08-23 | 2000-04-20 | Эн-Пи-Эс Фармасьютикалз, Инк. | Арилалкиламины, композиции, способы лечения и диагностики, способы идентификации соединения |
DK0724561T3 (da) | 1991-08-23 | 2004-06-28 | Nps Pharma Inc | Calciumreceptoraktive arylalkylaminer |
US6313146B1 (en) | 1991-08-23 | 2001-11-06 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US6011068A (en) | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US6031003A (en) * | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US6001884A (en) | 1991-08-23 | 1999-12-14 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US5162117A (en) | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
EP0637237B1 (de) | 1993-02-23 | 2004-05-19 | Brigham And Women's Hospital, Inc. | Calciumrezeptoraktive moleküle |
US6210714B1 (en) | 1993-11-23 | 2001-04-03 | Euro-Celtique S.A. | Immediate release tablet cores of acetaminophen having sustained-release coating |
UA41909C2 (uk) * | 1994-07-22 | 2001-10-15 | Елі Ліллі Енд Компані | Використання комбінації сполук для інгібірування остеопорозу, фармацевтичний препарат |
DE122005000033I1 (de) * | 1994-10-21 | 2005-09-29 | Nps Pharma Inc | Kalzium-Rezeptor aktive Verbindungen. |
GB9424766D0 (en) | 1994-12-07 | 1995-02-08 | Wellcome Found | Pharmaceutical composition |
GB9501127D0 (en) | 1995-01-20 | 1995-03-08 | Wellcome Found | Tablet |
DE19530575A1 (de) | 1995-08-19 | 1997-02-20 | Gruenenthal Gmbh | Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz |
ATE430123T1 (de) | 1996-05-01 | 2009-05-15 | Nps Pharma Inc | Inorganische am ionen-rezeptor aktive verbindungen |
US5837292A (en) * | 1996-07-03 | 1998-11-17 | Yamanouchi Europe B.V. | Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug |
WO1998001417A1 (fr) | 1996-07-08 | 1998-01-15 | Kirin Beer Kabushiki Kaisha | Composes actifs comme recepteurs du calcium |
DE19637082A1 (de) | 1996-09-12 | 1998-03-19 | Boehringer Mannheim Gmbh | Schnellzerfallende Pellets |
TW483881B (en) | 1996-12-03 | 2002-04-21 | Nps Pharma Inc | Calcilytic compounds |
IE970588A1 (en) | 1997-08-01 | 2000-08-23 | Elan Corp Plc | Controlled release pharmaceutical compositions containing tiagabine |
WO1999009458A1 (de) | 1997-08-13 | 1999-02-25 | OCé PRINTING SYSTEMS GMBH | Druck- oder kopiergerätesystem zum performanceangepassten erstellen einer vorgegebenen blattfolge von monochrom und/oder farbig bedruckten einzelblättern |
WO1999044580A1 (en) | 1998-03-06 | 1999-09-10 | Eurand International S.P.A. | Fast disintegrating tablets |
US6525084B2 (en) | 1998-07-23 | 2003-02-25 | Novo Nordisk A/S | Stable pharmaceutical formulation |
US6172091B1 (en) | 1998-10-14 | 2001-01-09 | Ortho-Mcneil Pharmaceutical, Inc. | 1,2-Disubstituted cyclopropanes |
ATE275342T1 (de) | 1998-11-23 | 2004-09-15 | Monsanto Technology Llc | Hochkonzentrierte wässrige glyphosatzusammensetzungen |
UA74141C2 (uk) | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6447809B1 (en) * | 1999-05-11 | 2002-09-10 | Metagenics, Inc. | Composition for promoting healthy bone structure |
US6733780B1 (en) | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
FR2800735B1 (fr) | 1999-11-09 | 2002-02-01 | Centre Nat Rech Scient | Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation |
CA2394222A1 (en) | 1999-12-22 | 2001-06-28 | Pharmacia Corporation | Sustained-release formulation of a cyclooxygenase-2 inhibitor |
GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
WO2001078725A2 (en) | 2000-04-13 | 2001-10-25 | Synthon B.V. | Modified release formulations containing a hypnotic agent |
US6419954B1 (en) * | 2000-05-19 | 2002-07-16 | Yamanouchi Pharmaceutical Co., Ltd. | Tablets and methods for modified release of hydrophilic and other active agents |
FR2809396B1 (fr) | 2000-05-24 | 2005-10-14 | Centre Nat Rech Scient | Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation |
US6656492B2 (en) * | 2000-06-30 | 2003-12-02 | Yamanouchi Pharmaceutical Co., Ltd. | Quick disintegrating tablet in buccal cavity and manufacturing method thereof |
WO2002024230A1 (fr) | 2000-09-22 | 2002-03-28 | Takeda Chemical Industries, Ltd. | Preparations solides |
JP2002167327A (ja) * | 2000-09-22 | 2002-06-11 | Takeda Chem Ind Ltd | 固形製剤 |
US7049283B2 (en) * | 2000-12-06 | 2006-05-23 | Novartis Ag | Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
IN191028B (de) | 2001-05-17 | 2003-09-13 | Sun Pharmaceutical Ind Ltd | |
EP1401503B1 (de) | 2001-06-22 | 2007-05-09 | Pfizer Products Inc. | Pharmazeutische zusammensetzungen enthaltend eine feste dispersion eines im wasser schwerlöslichen arzneimittels und ein löslichkeitsteigerndes polymer |
EP1321142A1 (de) | 2001-12-21 | 2003-06-25 | Novartis AG | Feste orale Zubereitung mit Tegaserod |
WO2003086343A2 (en) | 2002-04-05 | 2003-10-23 | Cadila Healthcare Limited | Fast disintegrating oral dosage forms |
US20050147670A1 (en) * | 2002-05-29 | 2005-07-07 | Impax Laboratories Inc. | Oral disintegrating dosage forms |
AU2003272767A1 (en) | 2002-09-30 | 2004-04-23 | Schering Corporation | Use of tricyclic amides for the treatment of disorders of calcium homeostasis |
GB0230015D0 (en) | 2002-12-23 | 2003-01-29 | Novartis Ag | Organic compounds |
ES2401769T5 (es) | 2003-09-12 | 2020-07-01 | Amgen Inc | Formulación de disolución rápida de cinacalcet HCl |
ATE495747T1 (de) | 2004-08-23 | 2011-02-15 | Teva Pharma | Kristalline form des ibandronat-natriums und herstellungsverfahren dafür |
NL1028867C2 (nl) | 2005-04-26 | 2006-10-27 | Xycarb Ceramics B V | Inrichting voor het ondersteunen van een substraat alsmede een werkwijze voor het vervaardigen van een dergelijke inrichting. |
WO2009111876A1 (en) | 2008-03-11 | 2009-09-17 | The University Of Western Ontario | System and method for magnetic resonance imaging |
-
2004
- 2004-09-10 ES ES04781429T patent/ES2401769T5/es active Active
- 2004-09-10 EA EA200600566A patent/EA013425B1/ru unknown
- 2004-09-10 ES ES18175499T patent/ES2735226T3/es active Active
- 2004-09-10 ES ES19164145T patent/ES2812198T1/es active Pending
- 2004-09-10 CN CN2004800327959A patent/CN1946382B/zh active Active
- 2004-09-10 HU HUE18175499 patent/HUE044822T2/hu unknown
- 2004-09-10 DE DE19164145.5T patent/DE19164145T1/de active Pending
- 2004-09-10 SI SI200432474T patent/SI3395340T1/sl unknown
- 2004-09-10 DK DK04781429.8T patent/DK1663182T4/da active
- 2004-09-10 DK DK18175497.9T patent/DK3395339T3/da active
- 2004-09-10 EP EP14163366.9A patent/EP2821067B1/de active Active
- 2004-09-10 ES ES17185704T patent/ES2734057T3/es active Active
- 2004-09-10 EP EP04781429.8A patent/EP1663182B2/de active Active
- 2004-09-10 TR TR2019/10180T patent/TR201910180T4/tr unknown
- 2004-09-10 AR ARP040103266A patent/AR045637A1/es unknown
- 2004-09-10 WO PCT/US2004/026732 patent/WO2005034928A1/en active Application Filing
- 2004-09-10 PL PL18175497T patent/PL3395339T3/pl unknown
- 2004-09-10 SI SI200432475T patent/SI3395338T1/sl unknown
- 2004-09-10 SI SI200432018T patent/SI1663182T2/sl unknown
- 2004-09-10 SG SG200806469-3A patent/SG146608A1/en unknown
- 2004-09-10 BR BR122018013029-6A patent/BR122018013029B1/pt active IP Right Grant
- 2004-09-10 TR TR2019/10177T patent/TR201910177T4/tr unknown
- 2004-09-10 KR KR1020067003448A patent/KR101332058B1/ko active IP Right Grant
- 2004-09-10 EP EP17185704.8A patent/EP3260117B8/de active Active
- 2004-09-10 SI SI200432473T patent/SI3395339T1/sl unknown
- 2004-09-10 HU HUE17185704A patent/HUE043958T2/hu unknown
- 2004-09-10 EP EP18175497.9A patent/EP3395339B8/de not_active Revoked
- 2004-09-10 HU HUE14163366A patent/HUE035596T2/en unknown
- 2004-09-10 AU AU2004279318A patent/AU2004279318C1/en active Active
- 2004-09-10 CA CA2536487A patent/CA2536487C/en active Active
- 2004-09-10 EP EP19164145.5A patent/EP3578175B1/de active Active
- 2004-09-10 PT PT17185704T patent/PT3260117T/pt unknown
- 2004-09-10 DK DK18175499.5T patent/DK3395340T3/da active
- 2004-09-10 ES ES14163366.9T patent/ES2655435T3/es active Active
- 2004-09-10 PT PT18175499T patent/PT3395340T/pt unknown
- 2004-09-10 SI SI200432416T patent/SI2821067T1/en unknown
- 2004-09-10 ES ES18175497T patent/ES2735216T3/es active Active
- 2004-09-10 TW TW093127508A patent/TWI344363B/zh active
- 2004-09-10 US US10/937,870 patent/US7829595B2/en active Active
- 2004-09-10 PT PT18175495T patent/PT3395338T/pt unknown
- 2004-09-10 BR BRPI0414254A patent/BRPI0414254B8/pt active IP Right Grant
- 2004-09-10 HU HUE18175497A patent/HUE045411T2/hu unknown
- 2004-09-10 PL PL18175499T patent/PL3395340T3/pl unknown
- 2004-09-10 EP EP10014567A patent/EP2316442A1/de not_active Withdrawn
- 2004-09-10 PL PL18175495T patent/PL3395338T3/pl unknown
- 2004-09-10 ES ES18175495T patent/ES2737348T3/es active Active
- 2004-09-10 PT PT18175497T patent/PT3395339T/pt unknown
- 2004-09-10 PT PT141633669T patent/PT2821067T/pt unknown
- 2004-09-10 JP JP2006526096A patent/JP5026077B2/ja active Active
- 2004-09-10 SI SI200432472T patent/SI3260117T1/sl unknown
- 2004-09-10 PL PL14163366T patent/PL2821067T3/pl unknown
- 2004-09-10 EP EP18175499.5A patent/EP3395340B8/de not_active Revoked
- 2004-09-10 NZ NZ545498A patent/NZ545498A/en unknown
- 2004-09-10 PT PT47814298T patent/PT1663182E/pt unknown
- 2004-09-10 PL PL17185704T patent/PL3260117T3/pl unknown
- 2004-09-10 DK DK14163366.9T patent/DK2821067T3/en active
- 2004-09-10 TR TR2019/09267T patent/TR201909267T4/tr unknown
- 2004-09-10 HU HUE18175495 patent/HUE044279T2/hu unknown
- 2004-09-10 DK DK18175495.3T patent/DK3395338T3/da active
- 2004-09-10 MY MYPI20043684A patent/MY142046A/en unknown
- 2004-09-10 MX MXPA06002616A patent/MXPA06002616A/es active IP Right Grant
- 2004-09-10 EP EP18175495.3A patent/EP3395338B1/de not_active Revoked
- 2004-09-10 PL PL04781429T patent/PL1663182T5/pl unknown
- 2004-09-10 TR TR2019/10447T patent/TR201910447T4/tr unknown
- 2004-09-10 DK DK17185704.8T patent/DK3260117T3/da active
-
2006
- 2006-02-14 IL IL173737A patent/IL173737A/en active IP Right Grant
- 2006-02-23 IS IS8324A patent/IS3027B/is unknown
- 2006-04-03 ZA ZA200602710A patent/ZA200602710B/en unknown
- 2006-04-11 NO NO20061640A patent/NO335739B1/no unknown
-
2010
- 2010-11-09 US US12/942,646 patent/US9375405B2/en active Active
-
2012
- 2012-05-14 JP JP2012110758A patent/JP5849015B2/ja active Active
-
2013
- 2013-02-08 HR HRP20130114TT patent/HRP20130114T4/hr unknown
-
2014
- 2014-08-15 JP JP2014165378A patent/JP5940120B2/ja active Active
-
2016
- 2016-05-24 US US15/163,356 patent/US20160338975A1/en not_active Abandoned
-
2017
- 2017-11-20 CY CY20171101211T patent/CY1119609T1/el unknown
-
2018
- 2018-04-30 US US15/966,812 patent/US20180243238A1/en not_active Abandoned
- 2018-12-20 US US16/227,882 patent/US20190117592A1/en not_active Abandoned
-
2019
- 2019-06-28 CY CY20191100682T patent/CY1122259T1/el unknown
- 2019-07-10 CY CY20191100734T patent/CY1121812T1/el unknown
- 2019-07-10 CY CY20191100735T patent/CY1121814T1/el unknown
- 2019-07-18 CY CY20191100767T patent/CY1121820T1/el unknown
-
2020
- 2020-03-27 US US16/832,087 patent/US20200222340A1/en not_active Abandoned
- 2020-11-06 US US17/091,798 patent/US20210052518A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE19164145T1 (de) | Schnellauflösungsformulierung einer calcium-rezeptor-aktivverbindung | |
DE60316552T2 (de) | Tablette mit hohem wirkstoffgehalt | |
CA1307003C (en) | Phenyl carbamate | |
JP2015057451A (ja) | 徐放性アミノピリジン組成物の使用方法 | |
DE20321906U1 (de) | Pramipexol-Dosierform zur einmal täglichen Verabreichung | |
JP5025468B2 (ja) | メマンチン又はネラメキサンの直接圧縮によって製造された、飲用に適した即効型錠剤 | |
DE09004973T1 (de) | Formulierung mit gesteuerter Freisetzung | |
KR20070100291A (ko) | 직접 압축 제형 및 방법 | |
CA2476201A1 (en) | Modified release formulations of at least one form of tramadol | |
JP2020097591A (ja) | 免疫抑制製剤 | |
EP2988733A1 (de) | Pharmazeutische zusammensetzungen mit kristallinem macitentan | |
CH676201A5 (de) | ||
JP2022070923A (ja) | Pgi2-受容体アゴニストを含む組成物、およびその調製のためのプロセス | |
Jannin et al. | Exploring the possible relationship between the drug release of Compritol®-containing tablets and its polymorph forms using micro X-ray diffraction | |
CN114901271A (zh) | 包含萘普生钠滚柱压实颗粒的口服片剂及其制备方法和使用方法 | |
KR20090090369A (ko) | 정제의 형성 방법 | |
SK117794A3 (en) | Enatiomeric 1-phenyl-2-(2-pyridinyl)ethylamene for the treatment of neurogenerative disorders | |
AU2016268477B2 (en) | Pharmaceutical compositions | |
AU2004283436A1 (en) | Extended release pharmaceutical dosage form | |
EP0714661B1 (de) | Verfahren zur Herstellung Molsidomin-haltiger Tabletten | |
EP2416761A1 (de) | Desfesoterodin in form eines weinsäuresalzes | |
CN109248153B (zh) | 一种盐酸环苯扎林缓释制剂 | |
RU2810575C1 (ru) | Фармацевтическая композиция, включающая мемантин и цитиколин, а также лекарственная форма на основе указанной фармацевтической композиции, включающей мемантин и цитиколин, способ ее получения и применение лекарственной формы на основе фармацевтической композиции, включающей мемантин и цитиколин | |
Mohammed et al. | Effects of a co-processed novel multifunctional excipient on the tablet properties of metronidazole | |
DE10206241A1 (de) | Arzneimittelformulierung enthaldend einen LTB Antagonisten |